Sanofi: Hemophilia Drug Trial Data Highlight Broad Use Potential

Data showing Sanofi’s experimental hemophilia drug fitusiran achieved the primary and secondary endpoints in two Phase 3 studies recently published in The Lancet and The Lancet Haematology journals highlight its potential to address unmet needs across all types of the bleeding disorder, company says in statement.

• The studies, presented at the American Society of Hematology meeting in 2021, evaluated the efficacy and safety of fitusiran, an investigational siRNA therapy for the prophylactic treatment of adults and adolescents with hemophilia A or B
• Across both trials, prophylactic treatment with fitusiran reduced annualized bleeding rates by 90% compared to the control arms, ...